[Botulinum toxin type A (BOTOX) for treatment of XXXX : an open label, dose-response study].

@entity1 @entity9663
The clinical effect of Botulinum Toxin Type A (BOTOX) were studied in @entity1 with @entity9663 . Clinical symptoms were evaluated with Jankovic's rating scale, widely used for @entity9663 . To see dose response, eyelid muscle force of the @entity1 was measured with a device recently developed for measurement of eyelid muscle force. The results showed significant improvement (p = 0.0000) on Jankovic's rating scale in all @entity1 groups after effective dose injections of 0.5, 1.25, and 2.5 U/site. Particularly the number of @entity1 with marked improvement (decrease of six points or more in total score on Jankovic's rating scale) increased with higher dose injections. The eyelid muscle force also decreased by 33.2 +/- 28.1%, 41.7 +/- 25.1%, and 69.6 +/- 5.0% in @entity1 groups after effective dose injections of 0.5, 1.25, and 2.5 U/site, respectively. The decrease of the eyelid muscle force showed significant dose response (p = 0.0254). Mean duration of effect was 12.9 weeks in @entity1 after effective dose injections of 1.25 U/site, which was significantly longer (p = 0.0205) than that of 9.6 weeks in @entity1 after effective dose injections of 0.5 U/site. No severe adverse effects were observed. We concluded that BOTOX injections of 1.25 U/site or more are a safe and effective treatment of @entity9663 .
